Melanoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797458
  • Drug Pipelines
  • 291 pages
  • Datamonitor Healthcare
1 of 3
Immune checkpoint inhibitors Yervoy, Opdivo, and Keytruda will be the key drivers of growth in the melanoma market.

This report addresses the following questions:

- How will the patent expiries of key brands impact melanoma market sales?
- What will differentiate immune checkpoint inhibitors such as Yervoy, Opdivo, and Keytruda from the rest of the marketed therapies for melanoma?
- Which marketed drugs or combination therapies will dominate the BRAF mutation-positive melanoma segment?
- Considering its cost and safety profile, what is the commercial potential of Imlygic?
- Which pipeline drugs address the unmet needs of NRAS mutation-positive melanoma patients?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: MELANOMA

- Executive Summary
- Market Overview and Trends
- Pricing and Reimbursement
- Market Definition and Methodology
- binimetinib
- Cotellic (cobimetinib),
- encorafenib
- Imlygic (talimogene laherparepvec)
- Keytruda (pembrolizumab),
- Mekinist (trametinib),
- Opdivo (nivolumab)
- Tafinlar (dabrafenib)
- Yervoy (ipilimumab)
- Zelboraf (vemurafenib)
- Primary Research Methodology

TREATMENT: MELANOMA

- Executive Summary
- Primary Research Methodology.
- Disease Definition and Diagnosis,
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: MELANOMA

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: MELANOMA

- Executive Summary
- Product Overview
- Product profile: Cotellic
- Product profile: Imlygic
- Product profile: Keytruda
- Product profile: Mekinist
- Product profile: Opdivo
- Product profile: Tafinlar
- Product profile: Yervoy
- Product profile: Zelboraf

PIPELINE: MELANOMA

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): binimetinib
- Product profile (late stage): encorafenib
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll